ZEVASKYN® (prademagene zamikeracel), developed by Abeona Therapeutics, is the first and only autologous cell sheet-based gene therapy indicated for the treatment of wounds in adult and pediatric patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB).
Made from your own skin cells that have been gene-modified to express functional collagen 7, ZEVASKYN sheets help address the genetic cause of RDEB in treated wounds. Up to 12 credit card–sized sheets (41.25 cm2 each) are applied to cover multiple individual wounds or joined together to cover larger areas.
Overview
|
EB Type |
Recessive Dystrophic Epidermolysis Bullosa (RDEB) |
|---|---|
|
Approved Age |
Approved for use in both adult and pediatric patients with RDEB. |
|
Product Description |
ZEVASKYN is made from your own skin cells that are gene modified to express functional collagen 7. It is applied surgically at a Qualified Treatment Center in an operating room under general or other appropriate anesthesia.
|
|
Product Manufacturing |
|
|
Select Safety Information |
Serious allergic reactions, including anaphylaxis, may occur. There is a potential risk of developing cancer; lifelong monitoring is recommended. ZEVASKYN is made using human and animal materials, and there is a small risk of infection transmission. The most common side effects are pain from the procedure and itching. Call your doctor for medical advice about side effects. |
|
Prescribing Information |
Full Prescribing Information |
Videos
Watch the Panel Discussion: Experiences with ZEVASKYN®
Hear from Lindy Ross, MD, Clinical Assistant Professor and Director of Pediatric Dermatology at the University of Texas Medical Branch, and Charlotte, an EB Community member and Strong Together Network™ participant who was treated with ZEVASKYN® (prademagene zamikeracel), in a panel discussion about their experiences with the treatment. Sponsored by Abeona Therapeutics.
Free registration is required to view the recording.
ZEVASKYN® (prademagene zamikeracel) is a type of gene therapy made from your own skin cells that is surgically applied to treat wounds in both children and adults who have recessive dystrophic epidermolysis bullosa (RDEB).
Serious side effects may occur, including allergic reactions, a potential risk of cancer, and risk of infection transmission. The most common side effects are pain from the procedure and itching. Please see the full Prescribing Information (PI).
ZEVASKYN® at the 2026 debra Care Conference
Hear from Daniela Russi, MD, Amy S. Paller, MSc, MD, Antonio Torres, and Lara Peck Hernandez in this session on ZEVASKYN® recorded at the debra Care Conference in Los Angeles, July 2026.
Getting Started
ZEVASKYN is available through ZEVASKYN Qualified Treatment Centers (QTCs), which are well-recognized EB treatment centers situated across the U.S.
Abeona Assist™ is Abeona’s comprehensive support program designed to provide personalized assistance every step of the way. The program helps patients understand how to access ZEVASKYN, reviews insurance coverage and financial assistance options, and offers travel and logistical support for eligible individuals.
For more information, to access ZEVASKYN support and resources, or to locate a ZEVASKYN Qualified Treatment Center (QTC), please call Abeona Assist or visit:
855-ABEONA-1 (855-223-6621)
Access ZEVASKYN Support and Resources
